The Effect of Duloxetine Treatment on Cognition in Patients With Fibromyalgia
Bibliographic Data
| ID | 19303883 |
|---|---|
| Authors | Richard Mohs, Richard C Mohs (0000-0002-3765-6287, Eli Lilly (United States)), Philip Mease, Lesley M Arnold (0000-0003-0393-9948), Fujun Wang (0000-0002-4283-4631), Jonna Ahl (0000-0002-5661-6053), Paula J Gaynor, Madelaine M Wohlreich (corresponding author) |
| Year | 2012 |
| Volume | 74 |
| Issue | 6 |
| Pages | 628-634 |
| Publication date | 2012-07-01 |
| Open Access | No |
| Type | ARTICLE |
| Venue | Psychosomatic Medicine (JOURNAL) |
| Journal identifiers | ISSN: 0033-3174 • E-ISSN: 1534-7796 |
| Publisher | Ovid Technologies (Wolters Kluwer Health) (PUBLISHER) |
| DOI | 10.1097/psy.0b013e31825b9855 |
| PMID | 22753629 |
| OpenAlex | W1998210533 |
| Language | EN |
| Citations received | 1 |
| References cited | 30 |
OBJECTIVES: To determine the effect of duloxetine treatment on cognition in patients with fibromyalgia. METHODS: Cognitive testing was conducted in a subset of adult patients in a randomized, double-blind, placebo-controlled trial of duloxetine. Patients met the American College of Rheumatology criteria for fibromyalgia and had a score of 4 or higher on the Brief Pain Inventory 24-hour average pain severity item. Patients who consented to cognitive testing were randomized to duloxetine (n = 80) or placebo (n = 76). The primary end point was at Week 12. Speed of processing on tasks requiring visual attention, working memory, and executive function was assessed with a Symbol Digit Substitution Test and Trail-Making Test A and B. Episodic memory was tested using the Verbal Learning and Recall Test. The change from baseline to end point (last-observation-carried-forward analysis) was analyzed by an analysis of covariance model, which included baseline, treatment, investigator, and treatment-by-investigator interaction. RESULTS: Most of the patients were white (89%) women (92%), ranging in age from 21 to 88 years. Mean scores on the cognitive tests were within 2 SD of published scores for similar-aged participants in the general population, indicating no substantial impairment. Baseline-to-end point changes in cognitive scores did not differ significantly between duloxetine and placebo treatment groups. CONCLUSIONS: Although scores differed somewhat from norms for age, substantial cognitive impairment was not evident in patients with fibromyalgia as assessed by the Symbol Digit Substitution Test, Trail-Making Test, and Verbal Learning and Recall Test. Overall, duloxetine treatment had neither positive nor negative effects on cognition. TRIAL REGISTRATION: Clintrials.gov NCT00673452
Cognition · Cognitive test · Digit symbol substitution test · Duloxetine · Fibromyalgia · Memory span · Neuropsychology · Physical therapy · Placebo · Psychiatry · Randomized controlled trial · Recall · Trail Making Test · Verbal learning · Working memory · Clinical Psychology · Fibromyalgia and Chronic Fatigue Syndrome Research · Internal Medicine · Medicine · Osteoarthritis Treatment and Mechanisms · Psychology · Psychosomatic Disorders and Their Treatments
| Citations per year | 0.2 |
|---|---|
| Citation span | 2021 - 2021 (1) |
| Highly cited | No |